Theses›Healthcare & bio›Metabolic wearables

Metabolic wearables

A full-stack metabolic wearable with a hard optical-sensing moat reaches venture scale by 2028, where the chip-supplier and OEM-feature models cannot

  • Bear
  • Early
  • $2.1B by 2035

The callGlucose belongs to Abbott and Dexcom; the open ground is a new optical biomarker, and the full-stack device that owns the customer and the data is the one that keeps the value.

D1D2R1R2R3C1foragainst D1D2R1R2R3C1foragainst
Fig. 1The balance. Drivers and catalysts against restraints, each block sized by its weight; catalysts hang dashed because they have not happened yet, sized by their odds. It tips toward the restraints.
  1. D1The GLP-1 wave makes metabolism something people newly want to measure, and OTC glucose proved in 2024 they will pay for it.
  2. D2Multi-wavelength optics on a photonic chip can read biomarkers LED heart-rate sensors cannot, without the filament under the skin that CGM patches need.
  3. R1No validated non-glucose consumer biomarker exists, and optical glucose stays in the graveyard; Apple's is still years away, if ever.
  4. R2Abbott, Dexcom and the watch makers can add any proven sensor to devices they ship in huge volume, so the window closes the moment a biomarker is proven.
  5. R3Rockley burned over $150M failing at exactly this, so the capability risk is real and expensive.
  6. C1CMS extending Medicare CGM coverage to non-insulin type 2 diabetes, about 10 million more people eligible; it grows the incumbents' lane, not the newcomer's.mid-2027
Rests onthe beliefs underneath
Supported by · confidence
What would prove itdated tests, open and resolved
202720282029today123456predictionswatch 202720282029today123456predictionswatch
Fig. 2Each ring is a dated test: dashed while open, struck through when overdue, ticked or crossed once resolved.
  1. 1By end-2027 at least one venture-backed full-stack metabolic wearable crosses $15M cumulative funding or 100k shipped units, while non-invasive optical glucose remains without consumer FDA/CE clearance.Dec 2027 · open
  2. 2A venture-backed full-stack metabolic wearable crossing $15M of funding or 100k shipped units on a non-glucose biomarker.Dec 2027 · open
  3. 3By end-2028, at least one independent, venture-backed full-stack metabolic wearable reaches venture scale on a metabolic biomarker beyond step/HR/SpO2.Dec 2028 · open
  4. 4Non-invasive optical glucose remains without consumer FDA/CE clearance through end-2028 (the graveyard holds).Dec 2028 · open
  5. 5One reaching venture scale, over $100M post-money and over $50M run-rate, while optical glucose stays uncleared.Dec 2028 · open
  6. 6An incumbent bundling a proven non-glucose biomarker into a watch or patch, which closes it.Dec 2028 · open
Expressionslisted, private, technologies
  • AAPLApple
    • expensive
  • ABTAbbott Laboratories
    • full
  • DXCMDexCom, Inc.
    • fair
  • 300298.SZSinocare
    • not screened
     iCan continuous glucose monitors and glucose meters sold to consumers and pharmacies, mainly in China.
  • PEPPepsiCo (Gatorade Gx)
    • not screened
     Gx Sweat Patch, a single-use patch measuring sweat sodium and fluid loss, sold to athletes with the Gx app.
Private · 12 private companies, 4 of them in the US.

Liom · Innopic · PhotonWear · Oura · Whoop · Ultrahuman · Abbott · Rockley Photonics · Levels · Signos · Epicore Biosystems · Liom (formerly Spiden)

3 more private companies tracked, not shown

Technologies
Who has already bet on itprivate rounds, from public sources

$369M raised by 6 companies, $175M of it in the last three years. Wave building: Money is arriving: recent rounds and tier-1 funds are in, but no runaway leader yet.

Backed by a top-tier venture firm: Levels, Signos. Backed by a strategic investor: Ultrahuman, Epicore Biosystems.

What changedthe record, newest first
  • 22 Jun 2026The metabolic-wearable winner will not be a sensor maker; it will be the company that owns the customer and their longitudinal data, using cheap miniaturised photonics to sense a biomarker the big watches cannot. Selling the sensor is the trap that killed Rockley.
  • 4 Jun 2026In spectral biosensing for consumer health, the value accrues to whoever owns the customer and the data, not to the chip. The bet is the team with a hard sensing breakthrough that goes full-stack to keep it.